-
Something wrong with this record ?
Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases
D. Negi, S. Granak, S. Shorter, VB. O'Leary, I. Rektor, SV. Ovsepian
Language English Country United States
Document type Journal Article
NLK
PubMed Central
from 2007
Europe PubMed Central
from 2007 to 1 year ago
ProQuest Central
from 2007-01-01 to 2023-10-31
Nursing & Allied Health Database (ProQuest)
from 2007-01-01 to 2023-10-31
Health & Medicine (ProQuest)
from 2007-01-01 to 2023-10-31
Psychology Database (ProQuest)
from 2007-01-01 to 2023-10-31
ROAD: Directory of Open Access Scholarly Resources
from 2007
- MeSH
- Alzheimer Disease * pathology MeSH
- Amyloid beta-Peptides MeSH
- Biomarkers MeSH
- Child MeSH
- Epilepsy * MeSH
- Humans MeSH
- Neurodegenerative Diseases * complications diagnosis MeSH
- tau Proteins MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
In neurodegenerative diseases, changes in neuronal proteins in the cerebrospinal fluid and blood are viewed as potential biomarkers of the primary pathology in the central nervous system (CNS). Recent reports suggest, however, that level of neuronal proteins in fluids also alters in several types of epilepsy in various age groups, including children. With increasing evidence supporting clinical and sub-clinical seizures in Alzheimer's disease, Lewy body dementia, Parkinson's disease, and in other less common neurodegenerative conditions, these findings call into question the specificity of neuronal protein response to neurodegenerative process and urge analysis of the effects of concomitant epilepsy and other comorbidities. In this article, we revisit the evidence for alterations in neuronal proteins in the blood and cerebrospinal fluid associated with epilepsy with and without neurodegenerative diseases. We discuss shared and distinctive characteristics of changes in neuronal markers, review their neurobiological mechanisms, and consider the emerging opportunities and challenges for their future research and diagnostic use.
Faculty of Engineering and Science University of Greenwich London Chatham Maritime Kent ME4 4TB UK
National Institute of Mental Health Topolova 748 Klecany 25067 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010538
- 003
- CZ-PrNML
- 005
- 20230801132503.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13311-023-01355-7 $2 doi
- 035 __
- $a (PubMed)36884195
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Negi, Deepika $u Faculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK
- 245 10
- $a Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases / $c D. Negi, S. Granak, S. Shorter, VB. O'Leary, I. Rektor, SV. Ovsepian
- 520 9_
- $a In neurodegenerative diseases, changes in neuronal proteins in the cerebrospinal fluid and blood are viewed as potential biomarkers of the primary pathology in the central nervous system (CNS). Recent reports suggest, however, that level of neuronal proteins in fluids also alters in several types of epilepsy in various age groups, including children. With increasing evidence supporting clinical and sub-clinical seizures in Alzheimer's disease, Lewy body dementia, Parkinson's disease, and in other less common neurodegenerative conditions, these findings call into question the specificity of neuronal protein response to neurodegenerative process and urge analysis of the effects of concomitant epilepsy and other comorbidities. In this article, we revisit the evidence for alterations in neuronal proteins in the blood and cerebrospinal fluid associated with epilepsy with and without neurodegenerative diseases. We discuss shared and distinctive characteristics of changes in neuronal markers, review their neurobiological mechanisms, and consider the emerging opportunities and challenges for their future research and diagnostic use.
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a neurodegenerativní nemoci $x komplikace $x diagnóza $7 D019636
- 650 _2
- $a proteiny tau $7 D016875
- 650 12
- $a Alzheimerova nemoc $x patologie $7 D000544
- 650 _2
- $a amyloidní beta-protein $7 D016229
- 650 12
- $a epilepsie $7 D004827
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Granak, Simon $u National Institute of Mental Health, Topolova 748, Klecany, 25067, Czech Republic
- 700 1_
- $a Shorter, Susan $u Faculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK
- 700 1_
- $a O'Leary, Valerie B $u Department of Medical Genetics, Third Faculty of Medicine, Charles University, Ruská 87, Prague, 10000, Czech Republic
- 700 1_
- $a Rektor, Ivan $u First Department of Neurology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Multimodal and Functional Neuroimaging Research Group, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Ovsepian, Saak V $u Faculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK. s.v.ovsepian@gre.ac.uk $1 https://orcid.org/0000000295224159
- 773 0_
- $w MED00167290 $t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics $x 1878-7479 $g Roč. 20, č. 3 (2023), s. 767-778
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36884195 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132459 $b ABA008
- 999 __
- $a ok $b bmc $g 1963141 $s 1196803
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 20 $c 3 $d 767-778 $e 20230308 $i 1878-7479 $m Neurotherapeutics $n Neurotherapeutics $x MED00167290
- LZP __
- $a Pubmed-20230718